14th – 19th April 2023
EPO will be present at the AACR Annual Meeting 2023 in Orlando, FL
EPO will be presenting its newest achievements in research and development at the AACR Annual Meeting in Orlando, Florida, held from 14th to 19th of April 2023. We will present posters and will be happy to meet you at the posters for lively discussions
- Poster # 5204: Preclinical models for translational immuno-oncology research: rare patient-derived xenografts on humanized mic
- Fully humanized mouse models for immuno-onoclogy research by co-transplantation of PDX and human hematopetic stem cells (HSC) or immune cells from whole blood (PBMCs, T, or NK cells).
- Several rare and difficult to establish tumor models have been investigated in humanized HSC mice.
- The models have been experimentally validated in preclinical studies with checkpoint inhibitors, novel bispeci¬c immune cell engagers (BITE) or cell therapy options such as CAR-T cells.
- Poster # 4674: Patient-derived xenograft and PDX-derived cell line models from glioblastoma for drug development and identification of
molecular signatures
- Establishment of 39 PDX glioma models on immunodeficient mice, fiveteen out of these by orthotopic (i.cer.) transplantation.
- Subcutaneously transplanted PDX models show individual growth and chemosensivity profiles and matching orthotopic PDX models have a reduced sensivity towards most tested drugs, possibly due to the blood-brain barrier and altered microenvironment.
- PDX-derived GBM cell cultures for in vitro pre-testing are free of murine cells, show individual morphology and similar response patterns towards selected drugs as their matching in vivo counterparts
- Poster # 44: An in vivo platform of pre-characterized renal cell carcinoma (RCC) patient-derived xenograft models allows the preclinical evaluation of patient-tailored intervention strategies
- A comprehensive panel of subcutaneous RCC PDX models with well-conserved molecular and pathological features.
- Drug screening towards four SoC drugs, targeting the VEGF and PI3K/mTOR pathway revealed individual and heterogeneous response profiles in these model which resembles the clinical situation.
- Intra-tumor heterogeneity can be assessed via PDX models from multi-tumor regions from one patient.